title: Clinical development of new treatments for diabetic macular oedema.
abstract: The benchmark treatment for diabetic macular oedema, the major cause of visual impairment in patients with diabetes mellitus, has traditionally been laser photocoagulation; however, as laser treatment does not always improve vision or even prevent further loss in many cases, several new pharmacotherapies that are injected into the vitreous for diabetic macular oedema have been successfully trialled over the past decade. Others are currently being evaluated. The two major classes of these drugs are steroids and vascular endothelial growth factor antagonists. In this article we briefly review the major clinical studies recently conducted in this field.
authors.affiliation: Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia. wsal7464@uni.sydney.edu.au
authors.forename: Wedad
authors.initials: W
authors.lastname: Salem
authors.forename: Samantha
authors.initials: S
authors.lastname: Fraser-Bell
authors.forename: Mark
authors.initials: M
authors.lastname: Gillies
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D000068258:Bevacizumab; D002387:Cataract Extraction; D003907:Dexamethasone / Q000008:administration & dosage; D003930:Diabetic Retinopathy / Q000628:therapy*; D006801:Humans; D017075:Laser Coagulation; D008269:Macular Edema / Q000628:therapy*; D011246:Pregnadienetriols / Q000627:therapeutic use; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D011246:Pregnadienetriols; C495058:pegaptanib; D000068258:Bevacizumab; C100065:flucloronide; D003907:Dexamethasone; D014222:Triamcinolone Acetonide